Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome: Molecular mimicry and host susceptibility

Neurology

Volumn 51, Issue 2, 1998, Pages 371-378

  Sheikh, K A ^a   Nachamkin, I ^c   Ho, T W ^a   Willison, H J ^h   Veitch, J ^h   Ung, H ^c   Nicholson, M ^d   Li, C Y ^e   Wu, H S ^f   Shen, B Q ^g   Cornblath, D R ^a   Asbury, A K ^c   McKhann, G M ^a,b   Griffin, J W ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e Second Teaching Hospital   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^h Pathology 509 ^*

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GANGLIOSIDE; LIPOPOLYSACCHARIDE;

ADULT; ARTICLE; CAMPYLOBACTER JEJUNI; CLINICAL ARTICLE; DEMYELINATION; DIARRHEA; GUILLAIN BARRE SYNDROME; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; INFECTION RISK; NEUROPATHY; PERIPHERAL NERVE; POLYNEUROPATHY; PRIORITY JOURNAL; SUBCLAVIAN STEAL SYNDROME; TREATMENT OUTCOME;

EID: 0031751872     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.51.2.371     Document Type: Article

References (41)

1. Yuki N, Handa S, Taki T, Kasama T, Takahashi M, Saito K. Cross-reactive antigen between nervous tissue and a bacterium elicits Guillain-Barré syndrome: molecular mimicry between gangliocide GM1 and lipopolysaccharide from Penner's serotype 19 of Campylobacter jejuni. Biomed Res 1992;13:451-453.
2. Kusunoki S, Chiba A, Kon K, et al. N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain-Barré syndrome. Ann Neurol 1994;35:570-576.
3. Fujimoto S, Yuki N, Itoh T, Amako K. Specific serotype of Campylobacter jejuni associated with Guillain-Barré syndrome. J Infect Dis 1992;165:183. Letter.
4. Yuki N, Sato S, Fujimoto S, Yamada Y, Kinoshita A, Itoh T. Serotype of Campylobacter jejuni, HLA, and the Guillain-Barré syndrome. Muscle Nerve 1992;16:968-969.
5. Kuroki S, Saida T, Nukina M, Haruta T, Yoshioka M, Kobayashi Y, Nakanishi H. Campylobacter jejuni strains from patients with Guillain-Barré syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues. Ann Neurol 1993;33:243-247.
6. Aspinall GO, Fujimoto S, McDonald AG, et al. Lipopolysaccharides from Campylobacter jejuni associated with Guillain-Barré syndrome patients mimic human gangliosides in structure. Infect Immun 1994;62:2122-2125.
7. Oomes PG, Jacobs BC, Hazenberg MPH, Banffer JRJ, van der Meché FGA. Anti-GM1 IgG antibodies and Campylobacter jejuni bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann Neurol 1995;38:170-175.
8. Aspinall GO, McDonald AG, Pang H, Kurjanczyk LA, Penner JL. Lipopolysaccharides of Campylobacter jejuni serotype O:19: structures of core oligosaccharide regions from the serostrain and two bacterial isolates from patients with the Guillain-Barré syndrome. Biochemistry 1994;33:241-249.
9. Ho TW, Mishu B, Li CY, et al. Guillain-Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 1995;118:597-605.
10. Rees JH, Gregson NA, Hughes RAC. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection. Ann Neurol 1995;38:809-816.
11. Rees JH, Soudain SE, Gregson NA, Hughes RA. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995;333:1374-1379.
12. Epidemiology of Campylobacter jejuni infections in the United States and other industrialized nations. In: Tauxe RV, Nachamkin I, Blaser MJ, Tompkins LS, eds. Campylobacter jejuni: current status and future trends. Washington, DC: American Society for Microbiology, 1992:9-19.
13. Mishu B, Blaser MJ. Role of infection due to Campylobacter jejuni in the initiation of Guillain-Barré syndrome. Clin Infect Dis 1993;17:104-108.
14. Bolton FJ, Robertson L. A selective medium for isolating Campylobacter jejuni/coli. J Clin Pathol 1982;35:462-467.
15. Hutchinson DN, Bolton FJ. Improved blood-free selective medium for the isolation of Campylobacter jejuni from faecal specimens. J Clin Pathol 1984;37:956-957.
16. Ho TW, Hsieh S-T, Nachamkin I, et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology 1997;48:717-724.
17. Penner JL, Hennessy JN. Passive hemagglutination techniques for serotyping Campylobacter fetus subsp: jejuni on the basis of soluble heat-stable antigens. J Clin Microbiol 1980;12: 732-737.
18. Lior H, Woodward DL, Edgar JA, Laroche LJ, Gill P. Serotyping of Campylobacter jejuni by slide agglutination based on heat labile antigenic factors. J Clin Microbiol 1982;15:761-768.
19. Nachamkin I, Bohachick K, Patton CM. Flagellin gene typing of Campylobacter jejuni by restriction fragment length polymorphism analysis. J Clin Microbiol 1993;31:1531-1536.
20. Nachamkin I, Ung H, Patton CM. Analysis of HL and O serotypes of Campylobacter by the flagellin gene typing system. J Clin Microbiol 1996;34:277-281.
21. Westphal O, Jann K. Bacterial lipopolysaccharides: extraction with phenol-water and further applications of the procedure. Methods Carbohydr Chem 1965;5:83-91.
22. Stevens TL, Bossie A, Sanders VM, et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988;334:255-258.
23. Tsai CM, Frasch CE. A sensitive silver stain for detecting LPS in polyacrylamide gels. Anal Biochem 1982;119:115-119.
24. Mishu B, Ilyas AA, Koski CL, et al. Serologic evidence of previous Campylobacter jejuni infection in patients with the Guillain-Barré syndrome. Ann Intern Med 1993;118:947-953.
25. Willison HJ, Paterson G, Kennedy PG, Veitch J. Cloning of human anti-GM1 antibodies from motor neuropathy patients. Ann Neurol 1994;35:471-478.
26. Yuki N, Takahashi M, Tagawa Y, Kashiwase K, Tadokoro K, Saito K. Association of Campylobacter jejunni serotype with antiganglioside antibody in Guillain-Barré syndrome and Fisher's syndrome. Ann Neurol 1997;42:28-33.
27. Gregson NA, Rees JH, Hughes RAC. Reactivity of serum IgG anti-GM1 ganglioside antibodies with the lipopolysaccharide fractions of Campylobacter jejuni isolates from patients with Guillain-Barré syndrome (GBS). J Neuroimmunol 1997;73: 28-36.
28. von Wulffen H, Hartard C, Scharein E. Seroreactivity to Campylobacter jejuni and gangliosides in patients with Guillain-Barré syndrome. J Infect Dis 1994;170:828-833.
29. Rees JH, Gregson NA, Hughes RA. Anti-ganglioside antibodies in patients with Guillain-Barré syndrome and Campylobacter jejuni infection. J Inf Dis 1995;172:605-606. Letter, comment.
30. Wijdicks EFM, Ropper AH. Acute relapsing Guillain-Barré syndrome after long asymptomatic intervals. Arch Neurol 1990;47:82-84.
31. Grand'maison F, Feasby TE, Hahn AF, Koopman WJ. Recurrent Guillain-Barré syndrome: clinical and laboratory features. Brain 1992;115:1093-1106.
32. Seyal M, Ziegler DK, Couch JR. Recurrent Guillain-Barré syndrome following influenza vaccine. Neurology 1978;28:725-726.
33. Rees JH, Vaughan RW, Kondeatis E, Hughes RAC. HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J Neuroimmunol 1995;62:53-57.
34. McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-342.
35. Sacks JJ, Lieb S, Baldy LM, et al. Epidemic campylobacteriosis associated with a community water supply. Am J Public Health 1986;76:424-429.
36. 1b ganglioside and lipopolysaccharides of Campylobacter jejuni isolated from patients with Fisher's syndrome. Ann Neurol 1994;36:791-793.
37. Jacobs BC, Hazenberg MP, Van Doom PA, Endtz HP, van der Meché FGA. Cross-reactive antibodies against gangliosides and Campylobacter jejuni lipopolysaccharides in patients with Guillain-Barré or Miller Fisher syndrome. J Infect Dis 1997; 175:729-733.
38. Sheikh KA, Deerinck TJ, Griffin JW, et al. Determination of the ultrastructural distribution of GM1- and asialo-GM1-like (Gal(b 1-3)GalNAc) epitopes in peripheral nerve fibers. Neurology 1997;48(suppl 3):281. Abstract.
39. O'Hanlon GM, Paterson GJ, Wilson G, et al. Anti-GM1 ganglioside antibodies cloned from autoimmune neuropathy patients show diverse binding patterns in the rodent nervous system. J Neuropathol Exp Neurol 1996;55:184-195.
40. Wirguin I, Suturkova-Milosevic L, Della-Latta P, Fisher T, Brown RH, Jr., Latov N. Monoclonal IgM antibodies to GM1 and asialo-GM1 in chronic neuropathies cross-react with Campylobacter jejuni lipopolysaccharides. Ann Neurol 1994; 35:698-703.
41. Li CY, Xue P, Gao CY, Tian WQ, Liu RC, Yang C. Experimental Campylobacter jejuni infection in the chicken: an animal model of axonal Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1996;61:279-284.